CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

10178	Companies
209339	Keywords
139437	Articles
110965	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 9 months 14 days ago

CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
CROSSJECT annonce le vif succès de son augmentation de capital à 5,7 millions d’euros après exercice intégral de la clause d’extension pour ZEPIZURE®

Financement Augmentation De Capital Pharmaceutique Crossject ZEPIZURE
PRESS RELEASE

published on 06/24/2025 at 19:00, 9 months 14 days ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 9 months 27 days ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
BRIEF

published on 06/11/2025 at 07:35, 9 months 27 days ago

CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour enfants

Pédiatrie Crossject Auto-injecteur Épilepsie ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 9 months 27 days ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
PRESS RELEASE

published on 06/11/2025 at 07:30, 9 months 27 days ago

CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour les crises d'épilepsie chez l'enfant, avec calibration réussie de ZENEO®. Étude clinique menée pour adapter l'injection aux enfants

Crossject Enfant ZENEO® Épilepsie ZEPIZURE® Junior
BRIEF

published on 06/06/2025 at 17:50, 10 months 2 days ago

Publication des droits de vote et actions de Crossject

Droits De Vote Capital Social Actions AMF Crossject
BRIEF

published on 06/06/2025 at 17:50, 10 months 2 days ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
PRESS RELEASE

published on 06/06/2025 at 17:45, 10 months 2 days ago

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
CROSSJECT publie le nombre total de droits de vote et d'actions au 31 mai 2025, incluant les informations sur son capital social et ses activités pharmaceutiques

Droits De Vote Capital Social Pharmaceutique Crossject Urgence
BRIEF

published on 06/04/2025 at 20:26, 10 months 4 days ago

CROSSJECT lance une augmentation de capital de près de 5 millions d'euros

Investissement Augmentation De Capital Pharmaceutique Droit Préférentiel De Souscription ZEPIZURE®

Accesswire

Published on 04/08/2026 at 23:00, 2 hours 55 minutes ago

NXT Energy Solutions Announces SFD Survey Contract
Published on 04/08/2026 at 22:05, 3 hours 50 minutes ago

GameSquare Achieves First Positive Adjusted EBITDA Quarter in Fourth Quarter, Marking Inflection to Operating Profitability
Published on 04/08/2026 at 18:45, 7 hours 10 minutes ago

Nano One to Receive Additional C$4.3M from the Government of Canada to Advance Battery Material Production for Energy Security & Defence
Published on 04/08/2026 at 18:45, 7 hours 10 minutes ago

Nano One recevra 4,3 M$ supplémentaires du gouvernement du Canada pour faire avancer la production de matériaux de batterie pour la sécurité énergétique et la défense
Published on 04/08/2026 at 16:08, 9 hours 47 minutes ago

Super Copper Announces Investor Relations Agreement

View all ACCESSWIRE

EQS Group

Published on 04/08/2026 at 23:54, 2 hours 1 minute ago

EQS-Adhoc: Raiffeisen Bank International AG: Raiffeisen Bank International AG announces its intention to launch a voluntary takeover offer to the shareholders of Addiko Bank AG
Published on 04/08/2026 at 23:30, 2 hours 24 minutes ago

AMPERA Officially Opens World Headquarters in Florida
Published on 04/08/2026 at 23:21, 2 hours 33 minutes ago

EQS-Adhoc: Raiffeisen Bank International AG: RBI announces intention to submit a voluntary public tender offer for all Addiko shares at EUR 23.05 per share
Published on 04/08/2026 at 21:03, 4 hours 51 minutes ago

EQS-Adhoc: Elmos Semiconductor SE: Cancellation of 540,000 treasury shares (approx. 3.05% of the share capital)
Published on 04/08/2026 at 18:10, 7 hours 45 minutes ago

PolyPeptide announces results of the annual General Meeting 2026

Les Echos

Published on 04/08/2026 at 18:17, 7 hours 37 minutes ago

Mise à disposition du Rapport sur la solvabilité et la situation financière 2025 du Groupe des Assurances du Crédit Mutuel
Published on 04/08/2026 at 18:16, 7 hours 38 minutes ago

Mise à disposition des états financiers 2025 du Groupe des Assurances du Crédit Mutuel
Published on 04/08/2026 at 18:02, 7 hours 53 minutes ago

Publication of the 2025 Universal Registration Document
Published on 04/08/2026 at 18:02, 7 hours 53 minutes ago

Mise à disposition du Document d'Enregistrement Universel 2025
Published on 04/08/2026 at 17:45, 8 hours 10 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE